Global CD33 Antibody Market Growth 2025-2031

Publication ID:

LPI04254847

Publication Date:

April 23, 2025

Pages:

114

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global CD33 Antibody market size is predicted to grow from US$ 536 million in 2025 to US$ 1108 million in 2031; it is expected to grow at a CAGR of 12.9% from 2025 to 2031.
CD33 Antibody is a specific antibody used to detect and study CD33 protein.
CD33 is a cell surface antigen that belongs to the immunoglobulin superfamily and is expressed in a variety of immune cells, especially in myeloid cells in the bone marrow. It plays a role in biological processes such as cell adhesion, immune regulation, and cell signaling. CD33 has been extensively studied in leukemia and other hematopoietic diseases because of its association with tumor cell differentiation and proliferation. CD33 antibodies can be used to study the expression and distribution of CD33, as well as its relationship with cell adhesion, cell signaling, leukemia, etc., and help to gain a deeper understanding of the function of CD33 in normal physiology and disease mechanisms. In addition, CD33 antibodies may also have potential application value in the diagnosis, treatment and monitoring of efficacy of leukemia.
The 鈥淐D33 Antibody Industry Forecast鈥� looks at past sales and reviews total world CD33 Antibody sales in 2024, providing a comprehensive analysis by region and market sector of projected CD33 Antibody sales for 2025 through 2031. With CD33 Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CD33 Antibody industry.
This Insight Report provides a comprehensive analysis of the global CD33 Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CD33 Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global CD33 Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CD33 Antibody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CD33 Antibody.
This report presents a comprehensive overview, market shares, and growth opportunities of CD33 Antibody market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Monoclonal Antibody
Polyclonal Antibody
Segmentation by Application:
Flow Cytometry
ELISA
Western Blot
Immunoprecipitation
Immunofluorescence
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sino Biological, Inc.
Cell Signaling Technology, Inc.
Bio-Techne
OriGene Technologies, Inc.
LifeSpan BioSciences, Inc
Abbexa
MyBiosource, Inc.
Biorbyt
Creative Biolabs
GeneTex
Arigo Biolaboratories Corp.
Abcam
RayBiotech, Inc.
Assay Genie
Key Questions Addressed in this Report
What is the 10-year outlook for the global CD33 Antibody market?
What factors are driving CD33 Antibody market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do CD33 Antibody market opportunities vary by end market size?
How does CD33 Antibody break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global CD33 Antibody Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for CD33 Antibody by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for CD33 Antibody by Country/Region, 2020, 2024 & 2031
2.2 CD33 Antibody Segment by Type
2.2.1 Monoclonal Antibody
2.2.2 Polyclonal Antibody
2.3 CD33 Antibody Sales by Type
2.3.1 Global CD33 Antibody Sales Market Share by Type (2020-2025)
2.3.2 Global CD33 Antibody Revenue and Market Share by Type (2020-2025)
2.3.3 Global CD33 Antibody Sale Price by Type (2020-2025)
2.4 CD33 Antibody Segment by Application
2.4.1 Flow Cytometry
2.4.2 ELISA
2.4.3 Western Blot
2.4.4 Immunoprecipitation
2.4.5 Immunofluorescence
2.4.6 Others
2.5 CD33 Antibody Sales by Application
2.5.1 Global CD33 Antibody Sale Market Share by Application (2020-2025)
2.5.2 Global CD33 Antibody Revenue and Market Share by Application (2020-2025)
2.5.3 Global CD33 Antibody Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global CD33 Antibody Breakdown Data by Company
3.1.1 Global CD33 Antibody Annual Sales by Company (2020-2025)
3.1.2 Global CD33 Antibody Sales Market Share by Company (2020-2025)
3.2 Global CD33 Antibody Annual Revenue by Company (2020-2025)
3.2.1 Global CD33 Antibody Revenue by Company (2020-2025)
3.2.2 Global CD33 Antibody Revenue Market Share by Company (2020-2025)
3.3 Global CD33 Antibody Sale Price by Company
3.4 Key Manufacturers CD33 Antibody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CD33 Antibody Product Location Distribution
3.4.2 Players CD33 Antibody Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for CD33 Antibody by Geographic Region
4.1 World Historic CD33 Antibody Market Size by Geographic Region (2020-2025)
4.1.1 Global CD33 Antibody Annual Sales by Geographic Region (2020-2025)
4.1.2 Global CD33 Antibody Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic CD33 Antibody Market Size by Country/Region (2020-2025)
4.2.1 Global CD33 Antibody Annual Sales by Country/Region (2020-2025)
4.2.2 Global CD33 Antibody Annual Revenue by Country/Region (2020-2025)
4.3 Americas CD33 Antibody Sales Growth
4.4 APAC CD33 Antibody Sales Growth
4.5 Europe CD33 Antibody Sales Growth
4.6 Middle East & Africa CD33 Antibody Sales Growth
5 Americas
5.1 Americas CD33 Antibody Sales by Country
5.1.1 Americas CD33 Antibody Sales by Country (2020-2025)
5.1.2 Americas CD33 Antibody Revenue by Country (2020-2025)
5.2 Americas CD33 Antibody Sales by Type (2020-2025)
5.3 Americas CD33 Antibody Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD33 Antibody Sales by Region
6.1.1 APAC CD33 Antibody Sales by Region (2020-2025)
6.1.2 APAC CD33 Antibody Revenue by Region (2020-2025)
6.2 APAC CD33 Antibody Sales by Type (2020-2025)
6.3 APAC CD33 Antibody Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe CD33 Antibody by Country
7.1.1 Europe CD33 Antibody Sales by Country (2020-2025)
7.1.2 Europe CD33 Antibody Revenue by Country (2020-2025)
7.2 Europe CD33 Antibody Sales by Type (2020-2025)
7.3 Europe CD33 Antibody Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa CD33 Antibody by Country
8.1.1 Middle East & Africa CD33 Antibody Sales by Country (2020-2025)
8.1.2 Middle East & Africa CD33 Antibody Revenue by Country (2020-2025)
8.2 Middle East & Africa CD33 Antibody Sales by Type (2020-2025)
8.3 Middle East & Africa CD33 Antibody Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CD33 Antibody
10.3 Manufacturing Process Analysis of CD33 Antibody
10.4 Industry Chain Structure of CD33 Antibody
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CD33 Antibody Distributors
11.3 CD33 Antibody Customer
12 World Forecast Review for CD33 Antibody by Geographic Region
12.1 Global CD33 Antibody Market Size Forecast by Region
12.1.1 Global CD33 Antibody Forecast by Region (2026-2031)
12.1.2 Global CD33 Antibody Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global CD33 Antibody Forecast by Type (2026-2031)
12.7 Global CD33 Antibody Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Sino Biological, Inc.
13.1.1 Sino Biological, Inc. Company Information
13.1.2 Sino Biological, Inc. CD33 Antibody Product Portfolios and Specifications
13.1.3 Sino Biological, Inc. CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sino Biological, Inc. Main Business Overview
13.1.5 Sino Biological, Inc. Latest Developments
13.2 Cell Signaling Technology, Inc.
13.2.1 Cell Signaling Technology, Inc. Company Information
13.2.2 Cell Signaling Technology, Inc. CD33 Antibody Product Portfolios and Specifications
13.2.3 Cell Signaling Technology, Inc. CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Cell Signaling Technology, Inc. Main Business Overview
13.2.5 Cell Signaling Technology, Inc. Latest Developments
13.3 Bio-Techne
13.3.1 Bio-Techne Company Information
13.3.2 Bio-Techne CD33 Antibody Product Portfolios and Specifications
13.3.3 Bio-Techne CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Bio-Techne Main Business Overview
13.3.5 Bio-Techne Latest Developments
13.4 OriGene Technologies, Inc.
13.4.1 OriGene Technologies, Inc. Company Information
13.4.2 OriGene Technologies, Inc. CD33 Antibody Product Portfolios and Specifications
13.4.3 OriGene Technologies, Inc. CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 OriGene Technologies, Inc. Main Business Overview
13.4.5 OriGene Technologies, Inc. Latest Developments
13.5 LifeSpan BioSciences, Inc
13.5.1 LifeSpan BioSciences, Inc Company Information
13.5.2 LifeSpan BioSciences, Inc CD33 Antibody Product Portfolios and Specifications
13.5.3 LifeSpan BioSciences, Inc CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 LifeSpan BioSciences, Inc Main Business Overview
13.5.5 LifeSpan BioSciences, Inc Latest Developments
13.6 Abbexa
13.6.1 Abbexa Company Information
13.6.2 Abbexa CD33 Antibody Product Portfolios and Specifications
13.6.3 Abbexa CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Abbexa Main Business Overview
13.6.5 Abbexa Latest Developments
13.7 MyBiosource, Inc.
13.7.1 MyBiosource, Inc. Company Information
13.7.2 MyBiosource, Inc. CD33 Antibody Product Portfolios and Specifications
13.7.3 MyBiosource, Inc. CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 MyBiosource, Inc. Main Business Overview
13.7.5 MyBiosource, Inc. Latest Developments
13.8 Biorbyt
13.8.1 Biorbyt Company Information
13.8.2 Biorbyt CD33 Antibody Product Portfolios and Specifications
13.8.3 Biorbyt CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Biorbyt Main Business Overview
13.8.5 Biorbyt Latest Developments
13.9 Creative Biolabs
13.9.1 Creative Biolabs Company Information
13.9.2 Creative Biolabs CD33 Antibody Product Portfolios and Specifications
13.9.3 Creative Biolabs CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Creative Biolabs Main Business Overview
13.9.5 Creative Biolabs Latest Developments
13.10 GeneTex
13.10.1 GeneTex Company Information
13.10.2 GeneTex CD33 Antibody Product Portfolios and Specifications
13.10.3 GeneTex CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 GeneTex Main Business Overview
13.10.5 GeneTex Latest Developments
13.11 Arigo Biolaboratories Corp.
13.11.1 Arigo Biolaboratories Corp. Company Information
13.11.2 Arigo Biolaboratories Corp. CD33 Antibody Product Portfolios and Specifications
13.11.3 Arigo Biolaboratories Corp. CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Arigo Biolaboratories Corp. Main Business Overview
13.11.5 Arigo Biolaboratories Corp. Latest Developments
13.12 Abcam
13.12.1 Abcam Company Information
13.12.2 Abcam CD33 Antibody Product Portfolios and Specifications
13.12.3 Abcam CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Abcam Main Business Overview
13.12.5 Abcam Latest Developments
13.13 RayBiotech, Inc.
13.13.1 RayBiotech, Inc. Company Information
13.13.2 RayBiotech, Inc. CD33 Antibody Product Portfolios and Specifications
13.13.3 RayBiotech, Inc. CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 RayBiotech, Inc. Main Business Overview
13.13.5 RayBiotech, Inc. Latest Developments
13.14 Assay Genie
13.14.1 Assay Genie Company Information
13.14.2 Assay Genie CD33 Antibody Product Portfolios and Specifications
13.14.3 Assay Genie CD33 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Assay Genie Main Business Overview
13.14.5 Assay Genie Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂